Novo Nordisk Could Benefit From Latest Fda Warning | Latest News RSS feed

Novo Nordisk Could Benefit From Latest Fda Warning - Latest News


Novo Nordisk Could Benefit From Latest FDA Warning

The FDA recently issued a warning about the linking of Fournier's gangrene with SGLT2 inhibitors used in the treatment of type-2 diabetes. Novo Nordisk claims that its GLP-1 analogues are better at tr... read more

FDA panel recommends approval of Novo Nordisk diabetes drug

The FDA is not obliged ... to start a patient on two new drugs at once. But certain patients in this group, such as those who were needle-shy, could benefit, they said. Dr. Todd Hobbs, U.S. chief medi... read more

Novo Nordisk: Strict US regulation threatens innovation

A stricter application of new medicine regulations in the US is threatening pharma innovation, according to Novo Nordisk's CEO Lars ... US due to safety issues. It could now be two years before Novo i... read more

Looking for another news?


Novo, Sanofi go head to head as FDA clears new diabetes drugs

(Reuters) - Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes ... so there were lots of patients who could benefit. Achieving Xultophy’s full potential ... read more


The Health 202: Utah voters approved expanding Medicaid, but that doesn't mean it will happen

AHH: New rules released by the Trump administration will expand veteran access to private health care, a move that could reduce the amount of time ... sent a letter to major insulin manufacturers Eli ... read more

Novo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 million

"At Novo Nordisk, we take our responsibility to communicate the safety and clinical benefits of our medicines ... which gained FDA approval in 2010. Victoza's FDA-approved labeling also contained a bo... read more

Trump’s Claim That His Efforts Brought Down Drug Prices Featured Prominently In Speech, But Facts Tell A Different Story

Lilly, along with other major insulin makers, Sanofi SA and Novo Nordisk ... industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan ... read more

The FDA Throws Novo Nordisk Off Course

When I wrote on Novo ... is developing a new follow-on to Lantus. Both of these are most likely to be 2015 launches. There is also the risk of competition from biosimilars, but I would argue that the ... read more

Pricing Pressure a Hard Pill for Pharma to Swallow

After accounting for rebates to pharmacy-benefit managers ... the vast majority of it.” Novo Nordisk is vulnerable because of pricing pressure on its diabetes treatments. “Insulin’s been around for 10... read more

U.S. FDA panel backs approval of Novo Nordisk diabetes drug

WASHINGTON, Oct 18 (Reuters) - Novo Nordisk A/S's new diabetes ... found that the benefit of reducing blood sugar overall offset this risk, which the company argues is transient. Analysts expect the d... read more

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

According to analysts, it could generate $1 billion in revenue for the company. The FDA typically follows the recommendations of its advisory panels. Just before the vote, Novo Nordisk shares rose 1.8 ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us